WHO classification–based prognostic scoring system for MDS
| Variable . | Score . | |||
|---|---|---|---|---|
| 0 . | 1 . | 2 . | 3 . | |
| WHO category | RA, RARS, 5q− | RCMD, RCMD-RS | RAEB-1 | RAEB-2 |
| Karyotype* | Good | Intermediate | Poor | — |
| Transfusion requirement† | No | Regular | — | — |
| Variable . | Score . | |||
|---|---|---|---|---|
| 0 . | 1 . | 2 . | 3 . | |
| WHO category | RA, RARS, 5q− | RCMD, RCMD-RS | RAEB-1 | RAEB-2 |
| Karyotype* | Good | Intermediate | Poor | — |
| Transfusion requirement† | No | Regular | — | — |
Reprinted from Malcovati et al13 with permission.
Risk groups: 0 indicates very low; 1, low; 2, intermediate; 3 to 4, high; and 5 to 6, very high. Score is obtained by adding the scores for each variable.
RA indicates refractory anemia; RARS, refractory anemia with ringed sideroblasts; 5q−, myelodysplastic syndrome with isolated del(5q) and marrow blasts less than 5%; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB-1, refractory anemia with excess of blasts-1; RAEB-2, refractory anemia with excess of blasts-2; and —, not applicable.
Karyotype was as follows: good, −Y, 5q−, NL; poor, −7, complex; and intermediate, all others.
RBC transfusion dependency was defined as having at least one RBC transfusion every 8 weeks over a period of 4 months.